α-synuclein fission yeast model: Concentration-dependent aggregation without plasma membrane localization or toxicity

Journal of Molecular Neuroscience

Volumn 28, Issue 2, 2006, Pages 179-191

  Brandis, Katrina A ^a   Holmes, Isaac F ^a   England, Samantha J ^a   Sharma, Nijee ^a   Kukreja, Lokesh ^a   DebBurman, Shubhik K ^a  

^a LAKE FOREST COLLEGE   (United States)

Author keywords

Neurodegeneration; Nucleation polymerization; Parkinson's disease; Protein aggregation; Schizosaccharomyces pombe; Synuclein

Indexed keywords

ALPHA SYNUCLEIN; THIAMINE;

ARTICLE; CELL INCLUSION; CELL MEMBRANE; COMPARATIVE STUDY; CONTROLLED STUDY; CYTOPLASM; DIFFUSION; GENE REPRESSION; GENE VECTOR; MOLECULAR MODEL; NONHUMAN; POLYMERIZATION; PROMOTER REGION; PROTEIN AGGREGATION; PROTEIN EXPRESSION; PROTEIN FOLDING; SACCHAROMYCES CEREVISIAE; SCHIZOSACCHAROMYCES POMBE; TOXICITY;

SACCHAROMYCES CEREVISIAE; SACCHAROMYCETALES; SCHIZOSACCHAROMYCES POMBE;

EID: 33646896726     PISSN: 08958696     EISSN: None     Source Type: Journal    
DOI: 10.1385/JMN:28:2:179     Document Type: Article

References (68)

1. Alfa C., et al., eds. (1993) Experiments with Fission Yeast, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York.
2. Auluck P., Chan E., Trojanowski J., Lee V., and Bonini N. (2002) Chaperone suppression of α-synuclein toxicity in a Drosophila model for Parkinson's disease. Science 295, 865-868.
3. Bussell R. Jr. and Eliezer D. (2004) Effects of Parkinson's disease-linked mutations on the structure of lipid-associated alpha-synuclein. Biochemistry 43, 4810-4818.
4. Caughey B. and Lansbury P. T. (2003) Protofibrils, pores, fibrils, and neurodegeneration: separating the responsible protein aggregates from the innocent bystanders. Annu. Rev. Neurosci. 26, 267-298.
5. Cole N. B., Murphy D. D., Grider T., Rueter S., Brasaemle D., and Nussbaum R. L. (2000) Lipid droplet binding and oligomerization properties of the Parkinson's disease protein alpha-synuclein. J. Biol. Chem. 277, 6344-6352.
6. Conway K., Harper J., and Lansbury P. (1998) Accelerated in vitro fibril formation by a mutant α-synuclein linked to early-onset Parkinson's disease. Nat. Med. 4, 1318-1320.
7. Conway K., Harper J., and Lansbury P. (2000) Fibrils formed in vitro from α-synuclein and two mutant forms linked to Parkinson's disease are typical amyloid. Biochemistry 39, 2552-2563.
8. Dauer W. and Przedborski S. (2003) Parkinson's disease: mechanisms and models. Neuron 39, 889-909.
9. Davidson W. S., Jonas A., Clayton D. F., and George J. M. (1998) Stabilization of alpha-synuclein secondary structure upon binding to synthetic membranes. J. Biol. Chem. 273, 9443-9449.
10. Davis L. and Smith G. R. (2001) Meiotic recombination and chromosome segregation in Schizosaccharomyces pombe. Proc. Natl Acad. Sci. U. S. A. 98, 8395-8402.
11. Dawson T. M. and Dawson V. L. (2003) Molecular pathways of neurodegeneration in Parkinson's disease. Science 302, 819-822.
12. Ding T. T., Lee S. J., Rochet J. C., and Lansbury P. T. Jr. (2002) Annular alpha-synuclein protofibrils are produced when spherical protofibrils are incubated in solution or bound to brain-derived membranes. Biochemistry 41, 10,209-10,217.
13. Dixon C., Mathias N., Zwieg R. M., Davis D. A., and Gross D. S. (2005) Alpha-Synuclein targets the plasma membrane via the secretory pathway and induces toxicity in yeast. Genetics 170, 47-59.
14. Eigen M. (1996) Prionics or the kinetic basis of prion diseases. Biophys. Chem. 63, A1-18.
15. Fantes P. and Beggs J. (2000). The Yeast Nucleus, Oxford University Press, Oxford, U.K.
16. Feany M. and Bender W. (2000) A Drosophila model of Parkinson's disease. Nature 23, 294-298.
17. Fernandez S., Homann M. J., Henry S. A., and Carman G. M. (1986) Metabolism of the phospholipid precursor inositol and its relationship to growth and viability in the natural auxotroph. Schizosaccharomyces pombe. J. Bacteriol. 166, 779-786.
18. George J. M., Jin H., Woods W. S., Clayton D. F. (1995) Characterisation of a novel protein regulated during the critical period for song-learning in the Zebra Finch. Neuron 15, 361-372.
19. Giasson B., Uryu K., Trojanowski J., and Lee V. (1999) Mutant and wild type human α-synucleins assemble into elongated filaments with distinct morphologies in vitro. J. Biol. Chem. 274, 7619-7622.
20. Goldberg M. S. and Lansbury P. T. Jr. (2000) Is there a cause and effect relationship between alpha-synuclein fibrillizationand Parkinson's disease? Nat. Cell Biol. 2, E115-119.
21. Haass C. and Steiner H. (2001) Protofibrils, the unifying toxic molecule of neurodegenerative disorders? Nat. Neurosci. 4, 859-860.
22. Hardy J. and Selkoe D. J. (2002) The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 297, 353-356.
23. Harper J. D. and Lansbury P. T. Jr. (1997) Models of amyloid seeding in Alzheimer's disease and scrapie: mechanistic truths and physiological consequences of the time-dependent solubility of amyloid proteins. Annu. Rev. Biochem. 66, 385-407.
24. Humphrey T. (2000) DNA damage and cell cycle control in Schizosaccharomyces pombe. Mutat. Res. 451, 211-226.
25. Irizarry M. C., Kim T. W., McNamara M., Tanzi R. E., George J. M., Clayton D. F., and Hyman B. T. (1996) Characterization of the precursor protein of the non-A β-component of senile plaques (NACP) in the human central nervous system. J. Neuropathol. Exp. Neurol. 55, 889-895.
26. Iwai A., Masliah E., Yoshimoto M., Ge N., Flanagan L., Rohan de Silva H. A., et al. (1995) The precursor protein of non-A; β-component of Alzheimer's disease amyloid is a presynaptic protein of the central nervous system. Neuron 14, 467-475.
27. Jarrett J. T. and Lansbury P. T. Jr. (1993) Seeding "one dimensional crystallization" of amyloid: a pathogenic mechanism in Alzheimer's disease and scrapie? Cell 73, 1055-1058.
28. Jensen P. H., Nielsen M., Jakes R., Dottis C. G., and Goedert M. (1998) Binding of α-synuclein to brain vesicles is abolished by familial Parkinson's disease mutation. J. Biol. Chem. 273, 26,292-26,294.
29. Jo E., Fuller N., Rand R. P., St George-Hyslop P., and Fraser P. E. (2002) Defective membrane interactions of familial Parkinson's disease mutant A30P alpha-synuclein. J. Mol. Biol. 315, 799-807.
30. Jo E., McLaurin J., Yip C. M., St George-Hyslop P., and Fraser P. E. (2000) Alpha-Synuclein membrane interactions and lipid specificity. J. Biol. Chem. 275, 34,328-34,334.
31. Kahle P. J., Neumann M., Ozmen L., Müller V., Jacobsen H., Schindzielorz A., et al. (2000) Subcellular localization of wild-type and Parkinson's disease-associated mutant α-synuclein in human and transgenic mouse brain. J. Neurosci. 20, 6365-6373.
32. Krobitsch S. and Lindquist S. (2000) Aggregation of huntingtin in yeast varies with the length of the polyglutamine expansion and the expression of chaperone proteins. Proc. Natl. Acad. Sci. U. S. A. 97, 1589-1594.
33. Kunst C., Mezey E., Brownstein M., and Patterson D. (1997) Mutations in SOD1 associated with amylotrophic lateral sclerosis cause novel protein interactions. Nat. Genet. 15, 91-94.
34. Lansbury P. T. Jr. (1999) Evolution of amyloid: what normal protein folding may tell us about fibrillogenesis and disease. Proc. Natl. Acad. Sci. U. S. A. 96, 3342-3344.
35. Lashuel H. A., Hartley D., Petre B. M., Walz T., and Lansbury P. T. Jr. (2002) Neurodegenerative diseases: amyloid pores from pathogenic mutations. Nature 418, 291.
36. Lasko M., Vartiainen S., Moilanen A., Sirvio J., Thomas J. H., Nass R., et al. (2003) Dopaminergic neuronal loss and motor deficits in Caenorhabditis elegans overexpressing human α-synuclein. J. Neurochem. 86, 165-172.
37. Lee H. J., Choi C., and Lee S. J. (2002) Membrane-bound α-synuclein has a high aggregation propensity and the ability to seed the aggregation of the cytosolic form. J. Biol. Chem. 277, 671-678.
38. Lee M. K., Stirling W., Xu Y., Xu X., Qui D., et al. (2002) Human alpha-synuclein-harboring familial Parkinson's disease-linked Ala-53 → Thr mutation causes neurodegenerative disease with alpha-synuclein aggregation in transgenic mice. Proc. Natl. Acad. Sci. U. S. A. 99, 8968-8973.
39. Li J., Uversky V. N., and Fink A. L. (2001) Effect of familial Parkinson's disease point mutations A30P and A53T on the structural properties, aggregation, and fibrillation of human alpha-synuclein. Biochemistry 40, 604-613.
40. Lotharius J. and Brundin P. (2002) Pathogenesis of Parkinson's disease: dopamine, vesicles and alpha-synuclein. Nat. Rev. Neurosci. 3, 932-942.
41. SC-like conformation in living cells. Nat. Cell Biol. 1, 358-361.
42. Maroteaux L. and Scheller R. H. (1991) The rat brain synucleins; family of proteins transiently expressed in the neuronal membrane. Mol. Brain Res. 11, 335-343.
43. McLean P. J., Kawamata H., Ribich S., and Hyman B. T. (2000) Membrane association and protein conformation of α-synuclein in intact neurons. Effect of Parkinson's disease-linked mutations. J. Biol. Chem. 275, 8812-8816.
44. Muchowski P. J., Ning K., D'Souza-Schorey C., and Fields S. (2002) Requirement of an intact microtubule cytoskeleton for aggregation and inclusion body formation by a mutant huntingtin fragment. Proc. Natl. Acad. Sci. U. S. A. 99, 727-732.
45. Narayanan V., Guo Y., and Scarlata S. (2005) Fluorescence studies suggest a role for alpha-synuclein in the phosphatidylinositol lipid signaling pathway. Biochemistry 44, 462-470.
46. Narhi L., Wood S. J., Steavenson S., Jiang Y., Wu G. M., Anafi D., et al. (1999) Both familial Parkinson's disease mutations accelerate α-synuclein aggregation. J. Biol. Chem. 274, 9843-9846.
47. Necula M., Chirita C. N., and Kuret J. (2003) Rapid anionic micelle-mediated alpha-synuclein fibrillization in vitro. J. Biol. Chem. 278, 46,674-46,680.
48. Olanow C. W. and Tatton W. A. (1999) Etiology and pathogenesis of Parkinson's disease. Annu. Rev. Neurosci. 22, 123-144.
49. Outeiro T. F. and Lindquist S. (2003) Yeast cells provide insight into alpha-synuclein biology and pathobiology. Science 203, 1772-1775.
50. Outeiro T. F. and Muchowski P. J. (2004) Molecular genetics approaches in yeast to study amyloid diseases. J. Mol. Neurosci. 23, 49-60.
51. Perrin R. J., Woods W. S., Clayton D. F., and George J. M. (2001) Exposure to long chain polyunsaturated fatty acids triggers rapid multimerization of synucleins. J. Biol. Chem. 276, 41,958-41,962.
52. Perrin R. J., Woods W. S., Clayton D. F., and George J. M. (2000) Interaction of human α-synuclein and Parkinson's disease variants with phospholipids. J. Biol. Chem. 275, 34,393-34,398.
53. Perutz M. F. and Windle A. H. (2001) Cause of neural death in neurodegenerative diseases attributable to expansion of glutamine repeats. Nature 412, 143,144.
54. Rochet J. C., Conway K. A., and Lansbury P. T. Jr. (2000) Inhibition of fibrillization and accumulation of prefibrillar oligomers in mixtures of human and mouse alpha-synuclein. Biochemistry 39, 10,619-10,626.
55. Rochet J. C., Outeiro T. F., Conway K. A., Ding T. T., Volles M. J., Lashuel H. A., et al. (2004) Interactions among alpha-synuclein, dopamine, and biomembranes: some clues for understanding neurodegeneration in Parkinson's disease. J. Mol. Neurosci. 23, 23-34.
56. Sharma N., Brandis K., Herrera S., Johnson B., Vaidya T., and DebBurman S. K. (2006) α-Synuclein budding yeast model: toxicity enhanced by impaired proteasome and oxidative stress. J. Mol. Neurosci. 28(2), 161-178.
57. Sharon R., Goldberg M., Bar I., Betensky R., Shen J., and Selkoe D. (2001) α-Synuclein occurs in lipid-rich high molecular weight complexes, binds fatty acids, and shows homology to the fatty-acid binding proteins. Proc. Natl. Acad. Sci. U. S. A. 98, 9110-9115.
58. Shibayama-Imazu T., Okahashi I., Omata K., Nakajo S., Ochiai H., Nakai Y., et al. (1993) Cell and tissue distribution and developmental change of neuron specific 14 kDa protein (phosphoneuroprotein 14). Brain Res. 622, 17-25.
59. Shtilerman M. D., Ding T. T., and Lansbury P. T. Jr. (2002). Molecular crowding accelerates fibrillization of alpha-synuclein: could an increase in the cytoplasmic protein concentration induce Parkinson's disease? Biochemistry 41, 3855-3860.
60. Sisodia S. S. (1998) Nuclear inclusions in glutamine repeat disorders: are they pernicious, coincidental, or beneficial? Cell 95, 1-4.
61. Spillantini, M., Schmidt M., Lee V., Trojanowski J., Jakes R., and Goedert M (1998) α-Synuclein in filamentous inclusions of Lewy bodies from Parkinson's disease. Proc. Natl. Acad. Sci. U. S. A. 95, 6469-6473.
62. Taylor J. P., Hardy J., and Fishbeck K. H. (2002) Toxic proteins in neurodegenerative disease. Science 296, 1991-1995.
63. Volles M. J. and Lansbury P. T. Jr. (2002) Vesicle permeabilization by protofibrillar alpha-synuclein is sensitive to Parkinson's disease-linked mutations and occurs by a pore-like mechanism. Biochemistry 41, 4595-4602.
64. Volles M. J., Lee S. J., Rochet J. C., Shtilerman M. D., Ding T. T., Kessler J. C., and Lansbury P. T. Jr. (2001) Vesicle permeabilization by protofibrillar alpha-synuclein: implications for the pathogenesis and treatment of Parkinson's disease. Biochemistry 40, 7812-7819.
65. Willingham S., Outeiro T. F., DeVit M. J., Lindquist S., and Muchowski P. J. (2003) Yeast genes that enhance the toxicity of a mutant huntingtin or α-synuclein. Science 302, 1769-1772.
66. Wood S. J., Wypch J., Steavenson, S., Louis, J. C., Citron M., and Biere A. L. (1999). Alpha-synuclein fibrillogenesis is nucleation-dependent. Implications for the pathogenesis of Parkinson's disease. J. Biol. Chem. 274, 509-512.
67. Wood V., Gwilliam R., Rajandream M.A., et al. (2002). The genome sequence of Schizosaccharomyces pombe. Nature 415, 871-880.
68. Zabrocki P., Pellens K., Vanhelmont T., Vandebroek T, Griffioen G., Wera S., et al. (2005) Characterization of α-synuclein aggregation and synergistic toxicity of protein tau in yeast. FEBS J. 272, 1386-1400.